Development of a novel virus-like particle-based vaccine for preventing tick-borne encephalitis virus infection

作     者：Jielin Tang Muqing Fu Chonghui Xu Bao Xue Anqi Zhou Sijie Chen He Zhao Yuan Zhou Jizheng Chen Qi Yang Xinwen Chen Jielin Tang;Muqing Fu;Chonghui Xu;Bao Xue;Anqi Zhou;Sijie Chen;He Zhao;Yuan Zhou;Jizheng Chen;Qi Yang;Xinwen Chen

作者机构：Guangzhou National LaboratoryGuangzhou510005China State Key Laboratory of VirologyWuhan Institute of VirologyCenter for Biosafety Mega-ScienceChinese Academy of SciencesWuhan430071China Guangzhou Institutes of Biomedicine and HealthChinese Academy of SciencesGuangzhou510530China GMU-GIBH Joint School of Life SciencesGuangzhou Medical UniversityGuangzhou511436China State Key Laboratory of Respiratory DiseaseGuangzhou Medical UniversityGuangzhou511436China 

出 版 物：《Virologica Sinica》 (中国病毒学（英文版）)

年 卷 期：2023年第38卷第5期

页      面：767-777页

核心收录：

学科分类：0710[理学-生物学] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：This work was supported by grants from the National Key Research and Development Program of China(grant number:2018YFA0507201 to X.W.C.) the National Science Foundation of China(grant number:32000111 to Q.Y.) the China Postdoctoral Science Foundation(grant number:2020T130021ZX to Q.Y.and grant number:2020M672580 to Q.Y.) 

主　　题：Tick-borne encephalitis virus(TBEV) Virus-like particle(VLP) Immunogenicity Neutralization Vaccine 

摘      要：Tick-borne encephalitis virus(TBEV)is an important tick-borne pathogen that poses as a serious public health *** coverage and immunogenicity of the currently available vaccines against TBEV are relatively low;therefore,it is crucial to develop novel and effective vaccines against *** present study describes a novel strategy for the assembly of virus-like particles(VLPs)by co-expressing the structural(core/prM/E)and non-structural(NS2B/NS3Pro)proteins of *** efficacy of the VLPs was subsequently evaluated in C57BL/6 mice,and the resultant IgG serum could neutralize both Far-Eastern and European subtypes of *** findings indicated that the VLP-based vaccine elicited the production of cross-subtype reactive *** VLPs provided protection to mice lacking the type I interferon receptor(IFNAR^(-/-))against lethal TBEV challenge,with undetectable viral load in brain and intestinal ***,the group that received the VLP vaccine did not exhibit significant pathological changes and the inflammatory factors were significantly suppressed compared to the control *** with the VLP vaccine induced the production of multiple-cytokine-producing antiviral CD4+T cells in vivo,including TNF-α^(+),IL-2^(+),and IFN-γ^(+)T ***,the findings suggest that noninfectious VLPs can serve as a potentially safe and effective vaccine candidate against diverse subtypes of TBEV.